Evolving data about possible therapeutic targets for the treatment of transplant-associated thrombotic microangiopathy may introduce narsoplimab as a new therapy for management of patients with this challenging complication.
Evaluation of an expansion cohort of the pivotal phase I/II ZUMA-1 trial in patients with refractory large B-cell lymphoma revealed that early steroid intervention may have a positive impact on the toxicity profile of chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel, according to findings presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Use of an off-the-shelf chimeric antigen receptor T-cell product may be feasible for use in patients with relapsed/refractory B-cell malignancies for whom no other available therapies exist, according to results of a phase I trial in adult and pediatric patients that were presented at the 2020 Transplant & Cellular Therapies Meeting in Orlando, Florida.
Outpatient treatment with lisocabtagene maraleucel had consistent efficacy and safety with that of a previously reported clinical trial involving patients who were treated at university medical centers, according to results of 3 studies reported at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
In an interview with Targeted Oncology at the 2020 Transplantation & Cellular Therapy Meetings, Craig Sauter, MD, discussed the retrospective real-world review of patients with hematologic malignancies who developed cytopenia post-chimeric antigen receptor T-cell therapy.
Treating chronic graft-versus-host disease with ruxolitinib in both adult and pediatric patients was found to be safe and effective based on data from 2 separate single-center retrospective analyses whose results were presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.